GU Cast | Urology Podcast

Part 2 Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months.Part 2 today features controversies in PLND, the somewhat notorious ARPI switch control arm beloved of mCRPC trials, and teh importnt topic of de-escalation in advanced prostate cancer. Part 1 recently in your feeds included PSMA conundrums and triplet vs doublet therapy.

Even better on our YouTube channel

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. 

Special thanks to David Chen for help with videography

What are we to make of this large RCT of extended vs standard pelvic lymph node dissection (PLND) for prostate cancer?? Despite it not meeting its primary endpoint of improving biochemical recurrence, the authors now report in European Urology that it does reduce the incidence of distant metastases 10 years later! Go figure!
We chat with Dr Karim Touijer (MSKCC) and try to figure it out. We ask about data dredging, p-hacking and statistical shenanigans, and how adding two minutes and two extra lymph nodes to a PLND could possibly lead to reduced metastases.
Plus guest comments from Dr John Yaxley (Brisbane). What do you think??!! Will this change practice?? Will this change guidelines? Tune in and share your thoughts!

Even better on our YouTube channel
Links:
Paper in European Urology
Previous GU Cast with Karim discussing earlier paper (Feb 2022) 

Highlights from a GU Cast Live Event! Dr Kim Chi (Medical Oncologist, Vancouver) and Dr Carmen Mir (Urologist, Valencia) joined the PROSPECT meeting in Melbourne to discuss high-risk prostate cancer and mHSPC, along with many experts from around Australia. On the eve of the meeting over dinner, Declan Murphy led a GU Cast-themed panel discussion on five hot topics in prostate cancer, featuring snippets from GU Cast over the past few months. Part 1 today features PSMA conundrums and triplet vs doublet therapy.

Even better on our YouTube channel

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also support the PROSPECT meeting. 

Special thanks to David Chen for help with videography

A GU Cast Live Event!! Everything you need to know about treatment intensification in mHSPC!! Doublet vs Triplet. Who should have radiotherapy? PSMA PET/CT conundrums, e-escalation, case discussions and more. Featuring GU Cast Hosts Declan Murphy and Renu Eapen, Medical Oncologist Ben Tran, Nuclear Medicine Physician Louise Emmett, and Radiation Oncologist Amy Hayden. Plus lots of interaction from our live audience around Australia.
Watch the full webinar including presentations on our YouTube channel

This GU Cast Live Event was an interactive educational webinar supported by our Gold Partners, Mundipharma.

Learning objectives:
1. Provide an overview of the landscape of mHSPC today, with a particular focus on intensification of therapy
2. Provide an overview of the role of novel and conventional imaging in diagnosis of mHSPC, both synchronous
 and metachronous
3. To better understand options for intensification of systemic therapy in mHSPC
4. To better understand the role of radiotherapy in mHSPC

In the third of our special episodes focussing on GU Oncology in China, we are delighted to welcome back our GU Cast China Editor, Professor Yao Zhu, who has selected three huge prostate cancer highlights from the recent #ESMO24 meeting in Barcelona.  We are joined by Professor Shouzhen Chen (Qilu Hospital, Shandong University), and Professor Zhenhua Liu (Sichuan University, West China Hospital) to discuss PEACE-3, ARANOTE, and UpFront PSMA, and in particular to consider what these data mean to health care professionals and patients in China.
This is a Themed Podcast as part of our Gold Partnership with Bayer Pharmaceuticals in China. We are very grateful to Bayer China for helping us promote GU Cast in China and supporting these Themed Episodes.

Even better on our YouTube channel

You can also catch our recent full GU Cast Conference Highlights from #ESMO24 here 

Today we celebrate one of our favourite clinical trials - ENZAMET! It is 10 years since ENZAMET opened and beyond its pivotal data establishing that adding enzalutamide to ADT improves survival for mHSPC patients, it continues to produce a very strong stream of high-quality findings that affect our practice today. ENZAMET also straddled an epochal era which included the advent of doectaxel upfront in mHSPC, and the introduction of PSMA PET/CT.
Today we were very happy to speak to two of the principal architects of ENZAMET; Professor Ian Davis, Chair of the ANZUP co-operative trials group, and Professor Chris Sweeney. Director of the South Australian ImmunoGENomics Cancer Institute, who told us the extraordinary story of how this trial came about, the challenges and evolutions of its rollout, and the strong tail end of translational and other research which it continues to produce. It is a great example of how investigator initiated trials run by nimble and ambitious cooperative trial groups like ANZUP can do things a little differently.

This is a Themed Podcast supported by our Gold Partners, Astellas.

Een better on our YouTube channel

Links:
ANZUP
Previous podcast from #ANZUP24 Annual Scientific Meeting
ENZAMET 2019 paper NEJM
ENZAMET 2023 paper Lancet Oncology

Ask anyone which big oncology meeting gave us the best GU oncology highlights this year and the answer is easy! ESMO24 in Barcelona! Jammed full of key papers and so many highlights, Declan and Renu bring you a great overview in this GU Cast Conference Highlights from ESMO24.
Listen to discussions with investigators and key opinion leaders, interviews with delegates, a fun speed-walk through the prostate cancer poster session, and a fun morning at the OncoAlert 5K.

GU Cast Conference Highlights ares supported by our Conference Highlights Partner, Bayer China.

Even better on our YouTube channel

Penis Project is one of our favourite podcasts (and certainly popular with our patients), so we were delighted to welcome Host and Sexologist, Melissa Hadley-Barrett to join us for a chat. What is the Penis Project? Who is it for? (anyone with a penis, anyone who knows someone with a penis, or anyone who would like to have a penis apparently)! A cracking chat and we highly recommend subscribing. Just search Penis Project or browse the links below

Even better on our YouTube channel

Websites:
https://melissahadleybarrett.com   Men’s health only
https://rshealth.com.au/  All genders

SPECIAL OFFER - use the code MHB10 at the checkout on all the programs (penile rehab and erectile dysfunction and peyronies) or in the shop to get a 10% discount.
 
Facebook:
https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/
https://www.facebook.com/profile.php?id=100085146627814
 
Instagram:
https://www.instagram.com/melissahadleybarrett/
https://www.instagram.com/restorativehealth.clinic/
TikTok: @melissahadleybarrett
YouTube: Melissa Hadley Barrett
Linkedin:
https://www.linkedin.com/in/melissa-hadley-barrett/
TEDX
https://www.youtube.com/watch?v=IjHj1YTmLoA

The world's longest running live robotic surgery meeting took place in Bordeaux last week and Declan and Renu were there to bring you all the highlights! The 21st Meeting of the EAU Robotic Urology Section (ERUS) was their biggest ever with more than 1000 delegates watching more than 40 live surgeries from the world's top robotic surgeons. And this year includes some quite spectacular telesurgery with surgeons in Bordeaux and patients 8000km away in Beijing!! Renu takes a few new robots for a test drive, and we catch up with some of the biggest names in the business.
This is a Themed Episode supported by our Silver Partners,  Device Technologies Australia, distributors of the da Vinci Surgical System across Australia, New Zealand and South-East Asia

Even better on our YouTube channel

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.  We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.

This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel

Full paper in Lancet Oncology here